William “Billy” Lapp is the new Director of Sales, East Coast at Foley, Minnesota-based Artoss, Inc.
William Lapp New Director at Artoss

Lapp will be responsible for growing the sales of NanoBone Bone Graft from Maine to South Carolina and west to Ohio and for identifying, training, and managing independent distributors in that region.
Paul Byerley, managing director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopedic surgery, said, “Billy has built a very successful sales career with small companies in the biotech industry and more recently in orthobiologics and tissue regeneration. He is uniquely trained to articulate the key advantages of NanoBone to orthopaedic and neurosurgeons. He has earned the respect of distributor partners and I know he’ll contribute to the continued growth of NanoBone sales in the U.S.”
Lapp told OTW, “I am very excited to join what is already a very well-respected, established executive team lead by Jim Cassidy and Paul Byerley. They have set the foundation for Artoss, Inc. to become a leader in the orthobiologics space and my goal is to continue to build on that foundation by establishing a best-in-class distribution network throughout the east coast. I truly believe in two fundamental things: 1) It is important to be as knowledgeable as possible from a clinical perspective and, 2) To do things the right way; that is with credibility, integrity, and honesty. I believe by sticking to those things we will separate ourselves and experience incredible success.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.